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Background: Studies on the association between MDM2 SNP309 (T > G) and gastric cancer have reported
conflicting results. Thus, the aim of this study was to investigate whether MDM2 SNP309 is associated with
susceptibility and prognosis of gastric carcinoma in Chinese patients.
Methods: Total of 574 gastric carcinoma cases and 574 age- and sex-matched healthy controls were included.
MDM2 polymorphism was detected by PCR- RFLP and infection of Helicobacter pylori (H. pylori) by a validated
serology test. The functionality of MDM2 SNP309, with or without H. pylori lipopolysaccharide (LPS), was examined
by dual-luciferase assay. Kaplan-Meier survival curves were used to evaluate survival. Additional, a meta-analysis was
conducted to verity the findings.
Results: MDM2 SNP309G/G genotype was associated with an increased risk of gastric carcinoma when compared
with T/T genotype or T carriers (both P < 0.01), and a joint effect between MDM2 SNP309G/G and H. pylori infection
was observed to intensify gastric carcinoma risk. SNP309G/G was identified as an independent marker of poor
overall survival of carcinoma. In vitro, the luciferase assay further showed an increased transcriptional activity of
SNP309G allele compared with SNP309T allele, and the function of polymorphism T309G in MDM2 gene promoter
was intensified by H. pylori LPS. Pooled results from the meta-analysis confirmed that SNP309G/G genotype had a
significantly increased risk of gastric carcinoma compared with T/T genotype or T carriers, consistent with the case–
control findings.
Conclusions: MDM2 SNP309G allele is associated with an increased risk and poor prognosis of gastric carcinoma in
Chinese patients. Additional, there is a joint effect of MDM2 SNP309G/G allele and H. pylori infection on gastric
carcinoma development, which may attribute to H. pylori LPS.
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The p53 is well-known to be crucial in tumor prevention,
which is activated by stress and oncogene activation as a
transcription factor, and give rise to lots of cellular re-
sponses, such as cell cycle arrest, apoptosis, and senes-
cence [1]. More than 50% of human carcinomas exist p53
mutation or deletion [2]. MDM2 is an oncogene, encoding
E3 ubiquitin ligase, which negatively regulates p53 tran-
scriptional activity and protein stability [3], as it has been
reported that the embryonic lethality of MDM2 null mice
is caused by the uncontrolled activity of p53 and rescued
by its deletion [4]. MDM2 overexpression could inhibit
p53 function, and make damaged cells avoid the cell cycle
checkpoint control and become carcinogenic [5,6]. In
addition, there is a negative auto-regulatory feedback
loop between MDM2 and p53, which plays an important
role on regulating cell cycle progression, apoptosis and
senescence [3].
A T-to-G single nucleotide polymorphism (SNP) is lo-
cated 309 base pairs in promoter of MDM2, which known
as MDM2 SNP309 (T >G), has been found to enhance the
binding of the transcriptional activator specificity protein 1
(Sp1) to the P2 promoter of MDM2, resulting in an in-
creased MDM2 transcription and MDM2 protein expres-
sion, and a weaken of the p53 tumor suppression function
[7]. It’s important that the MDM2 SNP309G allele has been
shown with an increased risk for the development of some
tumors which express wild-type p53 [8-11].
H. pylori is a gram-negative pathogen that colonizes
approximately 50% of the world’s population, and is
identified as a cause of gastric carcinoma development
[12-14]. LPS of H. pylori is the constituent of its outer
membrane, which has been reported to have the ability
of promoting colonization of the mucus layer adjacent
to the gastric epithelial surface [15], and enhancing pro-
liferation and progression of gastric carcinoma [16,17].
Gastric carcinoma is the second most common reason
for carcinoma-related deaths, accounting for more than
1 million deaths every year worldwide [18]. Several stud-
ies have investigated the association between MDM2
polymorphism and gastric carcinoma susceptibility
[19-23]. However, these studies have produced inconsist-
ent and inconclusive results. In our previous study, we
reported that the MDM2 SNP309 (T > G) was associated
with gastric carcinoma in Chinese patients, especially
those with H. pylori infection [23]. However, that study
was of small sample size and did not address any func-
tional relation between MDM2 SNP309 (T > G) and gas-
tric carcinogenesis. Moreover, there has been no report
on the association between MDM2 SNP309 (T > G) and
survival of gastric carcinoma patients in Chinese pa-
tients. Therefore, our aim is to investigate whether
MDM2 SNP309 (T > G) is associated with susceptibility
and prognosis to gastric carcinoma in Chinese patients.Methods
Study population
574 gastric carcinoma patients and 574 healthy controls
were included. All subjects reside in Jiangsu Province of
China, and are unrelated ethnic Han Chinese. Patients
were consecutively recruited from July 2005 to July 2009,
at the First Affiliated Hospital of Nanjing Medical Univer-
sity. All cases were those newly histologically diagnosed
with gastric carcinoma without previous chemotherapy or
radiotherapy, which was staged and classified according
to the American Joint Committee on Cancer Staging
Manual, and Lauren’s classification, when diagnosed
[24,25]. All healthy controls were recruited from indi-
viduals living in the same residential areas who
attended routine medical examination at the same hos-
pital without no abnormal findings at the examination
and were age- (±5 years) and sex-matched to the cases.
All subjects who had a history of tumors including gas-
tric or other tumors or had undergone eradication
treatment for H. pylori were excluded.
Venous blood (2 ml) was collected from each subject
at the entry of the study for the genotyping and detec-
tion of H. pylori infection. Gastric carcinoma patients
were followed-up every 3 months by telephone or pa-
tient’s reexamination to the hospital to update the pro-
gress of the disease.
This study has been approved by the Ethics Commit-
tee of the First Affiliated Hospital of Nanjing Medical
University, and the written informed consent was
obtained from all subjects, and the institutional ethics
committees approving this research comply with accept-
able international standards (the Treaty of Helsinki).
Detection of H. pylori infection
The indirect solid phase immunochromatographic assay
was applied to detect the infection of H. pylori according
to its IgG antibodies (Genelabs Diagnostics Pty Ltd,
Singapore), which has been validated in Chinese popula-
tion with an accuracy of 92.3% [26].
Genotype analysis
Genomic DNA was extracted by proteinase K digestion
and followed by phenol–chloroform extraction and etha-
nol precipitation from a leukocyte pellet. Polymerase chain
reaction restriction fragment length polymorphism (PCR-
RFLP) was used to determine the genotype of MDM2
SNP309 [23]. In brief, the primer sequences were 5P-
CGCGGGAGTTCAGGGTAAAG-3P (forward) and 5P-
AGCTGGAGACAAGTCAGGACTTAAC-3P (reverse),
which generated the 237-bp fragment. The PCR product
was then digested by MSPA1I (New England Biolabs,
Bevely, MA, USA). The wild-type (SNP309T) allele pro-
duces a single 237-bp fragment and the variant
(SNP309G) allele produced two fragments of 189- and
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the case or control status. The gel images were read inde-
pendently by two research assistants. If a consensus was
not reached on the tested genotypes, then the genotyping
was repeated independently until a consensus was
reached. In addition, to validate the RFLP method, 100 (50
from cases and 50 from controls) PCR products were se-
lected randomly for direct sequencing with ABI 3700 se-
quencer, and the concurrence rate of these two methods
was 99%.
Construction of reporter plasmids
Because the association between MDM2 SNP309 (T >
G) and gastric carcinoma susceptibility, we then deter-
mined whether this polymorphism had an effect on gene
expression in vitro. The MDM2 promoter-luciferase re-
porter plasmids containing either 551 T or 787 G se-
quence were prepared by amplifying the 237 -bp MDM2
promoter region by using primers with restriction sites.
The primers were 5P-GACGCTAGCTTTGTCG-CGCA
GTTTCCACCG-3P (forward) and 5P-CGCGAAGCTT
CTTCTTG-CTCCATCTTTCC-3P (reverse), including
the NheI and HindIII restriction sites. We confirm
the amplified fragments by sequencing. The amplified
fragments and pGL3-basic vector (Promega, Beijing,
China) were cleaved by using the NheI and HindIII
enzymes (TaKaRa Biotech Co., Dalian, China). After
the fragments were cloned into the pGL3-basic vector,
the vectors were sequenced to confirm that there were
no wrong.
Cell culture
Human gastric cancer cell lines AGS and MKN45 and
mouse embryo fibroblast cell NIH-3 T3 (Institute of Cel-
lular Research, Chinese Academy of Science, Shanghai,
China) were maintained in RPMI-1640 medium
supplemented with 10% fetal bovine serum (FBS). All
the cells were incubated in a stable environment with
5% CO2 at 37°C in a humidified incubator (Thermo,
Forma Scientific, Inc., USA).
Transient transfection and luciferase assays
For transfection, NIH-3 T3, AGS and MKN45 cells were
seeded onto 24-well plates (100,000 cells per well), and
each well was cotransfected with 2.25 μg of the vector
DNA with either SNP309T or SNP309G allele and in-
ternal control 10 ng pRL-SV40, in which a cDNA could
encode the Renilla luciferase, and the pGL3-basic vector
without any insert was applied as the negative control.
After 24 h transfection, cells were lysed and luciferase
activity was assayed by using the Dual-Luciferase
Reporter Assay System (Promega) and normalized
according to the Renilla luciferase activity. Each plasmid
construct were done for independent triplicate.Purification and utilization of LPS
LPS was extracted from H. pylori strains (26695) using
the phenol-water extraction procedure previously de-
scribed [27], and was quantitated using the purpald
assay [28].
AGS cells were cotransfected with either MDM2
SNP309T or SNP309G luciferase reporters with Renilla
luciferase reporter (as internal control) for 24 h, followed
by incubation with two concentrations (0.1 and 1 μg/ml)
of H. pylori LPS for 24 h. Cells were lysed and luciferase
activity performed by using the Dual-Luciferase Reporter
Assay System (Promega) and normalized according to
the Renilla luciferase activity. Each plasmid construct
were done for independent triplicate.
Statistical analysis
Hardy-Weinberg equilibrium of alleles was evaluated by
chi-square test. Comparison of age between cases and
controls was evaluated by the Mann–Whitney U test,
and the difference in the distribution of genotypes be-
tween cases and controls was determined by chi-square
test. The association between the MDM2 SNP309 and
the risk for gastric carcinoma was estimated by odds ra-
tios (OR) with the 95% confidence intervals (CI). Logis-
tic regression was used to control for selected potential
confounders (sex, age, and H. pylori infection) and to as-
sess crude and adjusted OR and 95% CI. The difference
in the levels of luciferase reporter gene expression be-
tween different constructs was examined by student’s
test. Kaplan-Meier was used to construct the cumulative
overall survival curves and the difference was tested by
the log-rank test, and Cox’s proportional hazards model
was used to perform the multivariate analysis to adjust
for age, sex, TNM stage and H. pylori. All data analyses
were done using SPSS software (version 11.0, Chicago,
IL, USA). A P value of < 0.05 was considered statistically
significant. Our sample size of 574 gastric carcinoma pa-
tients and 574 controls provided a 93% power to test an
OR of 1.5 at the first error of 0.05 in a 2-sided test.
Meta-analysis
We identified related studies by searching the PubMed,
Embase, Web of Science, China National Knowledge In-
frastructure and Wanfang databases up to August 2012
with the search phrases of “murine double minute or
MDM2” and “polymorphism(s) or SNP309” and “gastric
or stomach” and “cancer or carcinoma or tumor or neo-
plasm”. Additional studies were checked by screening
reference lists of studies and reviews. The following cri-
teria were used for literature selection: (a) the case–con-
trol study of the association between MDM2 SNP309
polymorphism and gastric carcinoma susceptibility; (b)
genotypic frequencies in both cases and controls avail-
able. Only the study of most recent and complete was
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in our meta-analysis, containing 1935 cases and 2953
controls. The following information was collected from
each publication: the first author’s name, year of publica-
tion, country, number of cases and controls, and MDM2
genotype information.
The odds ratios (ORs) with 95% confidence intervals
(CIs) were pooled to assess the association between
MDM2 SNP309 and gastric carcinoma risk. The fixed ef-
fect model (Mantel-Haenszel method) and the random
effect model (the Dersimonian and Laird method) were
used to pool data from different studies [29,30]. If the
heterogeneity between studies is absent, the fixed effect
model was used; otherwise, the random effect model
was applied. The Z test was used to determine the statis-
tical significance of the OR. The chi-square-based Q test
and I2 were used to assess the statistical heterogeneity
between studies, heterogeneity was considered statisti-
cally significant when P ≤ 0.05 [30], and Ι2 was used to
qualify variation in OR attributable to heterogeneity.Table 1 Demographic, clinical and pathological characteristic
Characteristics Cases (n = 574)
Age (Mean ± SD, years) 58.56 ± 12.09
Sex (Male/female) 399/175
Seropositive rate of H. pylori infection 71.1%






















Median (Range) 36 (4–48)
Abbreviations: SD, standard deviation; NA, not applicable.The publication bias was estimated by the Egger’s test
[31]. P values < 0.05 are considered statistically signifi-
cant. All analysis was done by using the Review Manage
(v.4.2) and Statistical Analysis System software (v.9.1.3,
SAS Institute, Cary, NC).
Results
Patient characteristics
The cases and controls were well matched on sex and age.
The median age was 58.56 years (range, 21–90 years) for
cases and 58.29 years (range, 22–88 years) for controls.
There was no significance between cases and controls in
sex distribution (Table 1). H. pylori infection was detected
408 (71.1%) of cases and 390 (67.9%) controls (Table 1).
Association between MDM2 promoter SNP309
polymorphism and gastric carcinoma
The genotype frequencies of the controls (n = 574) were
consistent with the Hardy-Weinberg equilibrium distri-
bution (P = 0.98).s of study subjects
Controls (n = 574) P value value





















Table 2 The genotype distributions of MDM2 SNP309 in the cases with gastric carcinoma and healthy controls
Controls (n = 574) Patients (n = 574) Crude OR (95% CI) P value Adjusted OR (95% CI)† P value
Genotype
T/T 34.7% 30.1% 1.00
T/G 51.6% 45.3% 1.01 (0.78-1.32) 0.94 1.01 (0.78-1.31) 0.95
G/G 13.7% 24.6% 2.05 (1.46-2.89) < 0.01 2.06 (1.46-2.90) < 0.01
Recessive model
T carriers 86.3% 75.4% 1.00
G/G 13.7% 24.6% 2.04 (1.51-2.77) < 0.01 2.05 (1.51-2.78) < 0.01
Dominant model
T/T 31.2% 30.1% 1.00
G carriers 68.8% 69.9% 1.23 (0.96-1.58) 0.10 1.23 (0.96-1.58) 0.10
†Adjusted for age, sex, and H. pylori infection.
Abbreviations: OR, odds ratio; CI, confidence interval.
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of cases and controls are shown in Table 2. The MDM2
SNP309 genotype frequencies were 30.1% (T/T), 45. 3%
(T/G) and 24.6% (G/G) in cases, and 34.7% (T/T), 51.6%
(T/G) and 13.7% (G/G) in control subjects (P < 0.01).
The SNP309G/G genotype, but not SNP309T/G geno-
type, was associated with an increased risk of gastric car-
cinoma; the adjusted OR (95%CI) was 2.06 (1.46-2.90)
and 1.01 (0.78-1.31) for SNP309G/G homozygotes and
SNP309T/G heterozygotes, respectively, compared with
the SNP309T/T homozygotes. In the recessive model,
the SNP309G/G homozygote was associated with a 2.05-
fold increased risk of gastric carcinoma, compared with
the T carriers (adjusted OR, 2.05; 95% CI, 1.51-2.78; P <
0.01). Table 3 shows a significantly increased risk of gas-
tric carcinoma in patients with SNP309G/G genotype
and H. pylori infections (adjusted OR, 2.44, which was
greater than 1.14 × 1.94 = 2.21), compared with T carriers
without H. pylori infection.
Association of MDM2 SNP309 and gastric carcinoma in
relation to the location, metastatic status and TNM stage
of gastric carcinoma
The risks of subtypes of gastric carcinoma for SNP309G/
G were significantly increased when compared with T car-
riers, especially non-cardiac carcinoma (adjusted OR, 2.18;
95% CI, 1.57-3.04), lymph node metastasis presentTable 3 Association between MDM2 SNP309 and gastric carci





†Adjusted for age and sex.carcinoma (adjusted OR, 2.25; 95% CI, 1.63-3.12), liver
metastasis present carcinoma (adjusted OR, 3.34; 95% CI,
1.84-6.08), peritoneal dissemination present carcinoma
(adjusted OR, 2.13; 95% CI, 1.18-3.84), and advanced
stages carcinoma (adjusted OR, 2.30; 95% CI, 1.52-3.49 for
stage III, and 2.29; 95% CI, 1.42-3.69 for stage IV; Table 4).
Kaplan-Meier survival cures
Overall, 133 patients with gastric carcinoma were followed
up for a median (range) of 36 (4–48) months. Of the
101 patients with TNM stages II (T1N2-N3M0, T2N1-
N2M0, T3N0-N1M0, or T4aN0M0) to IV (TanyNanyM1),
SNP309 (G/G) homozygotes had a significant association
of poor overall survival (P < 0.01, Figure 1B). The differ-
ence in survival among SNP309 genotypes in 32 stage I
(T1N0-N1M0 or T2N0M0) patients was not significant
(P = 0.50, Figure 1A). In addition, Cox proportional haz-
ards analysis showed that SNP309 (G/G) was an inde-
pendent factor for poor prognosis of gastric carcinoma
with TNM II -IV stages (hazard ratio, 2.13; 95% CI, 1.04
to 4.36; P = 0.04) to adjust for sex, age, TNM stage and
H. pylori infection.
Effects of MDM2 SNP309 (T > G) on transcriptional activity
of MDM2 gene
As shown in Figure 2, the vectors with SNP309G allele
produced a 100% to 300% increase in the relativenoma in relation to H. pylori infection




2.44 (1.62-3.66) < 0.01
Table 4 Association between MDM2 SNP309 and gastric carcinoma in relation to location, metastasis and TNM stage
Variable MDM2 SNP309 genotype (Control/Case) Adjusted OR (95% CI) † P value
TT + TG GG TT + TG GG
Location
Cardia 495/141 79/40 1.00 1.84 (1.20-2.83) < 0.01
Non-cardia 495/292 79/101 1.00 2.18 (1.57-3.04) < 0.01
Vascular invasion
Absent 495/265 79/98 1.00 2.33 (1.67-3.26) < 0.01
Present 495/168 79/43 1.00 1.60 (1.06-2.42) 0.03
Lymph node metastasis 1.00
Absent 495/138 79/35 1.00 1.59 (1.02-2.47) 0.04
Present 495/295 79/106 1.00 2.25 (1.63-3.12) < 0.01
Liver metastasis 1.00
Absent 495/391 79/121 1.00 1.94 (1.42-2.65) < 0.01
Present 495/42 79/20 1.00 3.34 (1.84-6.08) < 0.01
Peritoneal dissemination
Absent 495/380 79/123 1.00 2.04 (1.49-2.79) < 0.01
Present 495/53 79/18 1.00 2.13 (1.18-3.84) 0.01
TNM stage
IA 495/75 79/21 1.00 1.75 (1.01-3.00) 0.04
IB 495/60 79/19 1.00 2.01 (1.13-3.57) 0.01
II 495/83 79/24 1.00 1.78 (1.06-2.98) 0.03
III 495/127 79/46 1.00 2.30 (1.52-3.49) < 0.01
IV 495/88 79/31 1.00 2.29 (1.42-3.69) < 0.01
†Adjusted for age, sex, and H. pylori infection.
Abbreviations: OR, odds ratio; CI, confidence interval.
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lele in all three types of cell lines (all P < 0.01). Further-
more, H. pylori LPS 1 μg/ml significantly increased the
relative luciferase activity, compared with untreated con-
trols in AGS cell, no matter whether SNP309T or
SNP309G allele was transfected (P < 0.01, Figure 3).
Meta-analysis of association between MDM2 promoter
SNP309 polymorphism and gastric carcinoma
We identified 4 published studies of the MDM2 SNP309
and gastric carcinoma susceptibility. With the combined
data from those previous studies and from our current
study, this meta-analysis included 1935 cases and 2953
controls. The characteristics of these studies are summa-
rized in Additional file 1: Table S1. The studies are all
Asian populations. As shown in Additional file 2: Table
S2 and Additional file 3: Table S3, compared with the
SNP309T/T genotype, the SNP309G/G genotype was
associated with a significant increased risk of gastric
carcinoma (OR, 1.57; 95% CI, 1.08-2.29; P = 0.02),
whereas the SNP309T/G genotype was not associated
significant with the risk of gastric carcinoma (OR, 1.08;
95% CI, 0.83- 1.41; P = 0.57). In the recessive model, theSNP309G/G homozygote was associated with a 1.51 -
fold increased risk of gastric carcinoma, compared with
the T carriers (95% CI, 1.21-1.89; P < 0.01). However, in
the dominant model, the G carriers was associated with
a 1.28-fold increased risk of gastric carcinoma, com-
pared with the SNP309T/T genotype (95% CI, 0.88-1.86;
P = 0.19). All stratified analyses are based on the recessive
model. When stratified analysis by location of gastric car-
cinoma, the SNP309G/G homozygote was associated with
a increased risk of gastric carcinoma, both in cardiac (OR,
1.65; 95% CI, 1.12-2.43; P = 0.01) and non- cardiac gastric
carcinoma (OR, 1.78; 95% CI, 1.42-2.23; P < 0.01) com-
pared with the T carriers. Stratified by the histologic sub-
type, the SNP309G/G homozygote was associated with a
1.37-fold significant increased risk of intestinal carcinoma
(95% CI, 1.04-1.81; P = 0.03), but not the diffuse carcin-
oma (OR, 1.05; 95% CI, 0.76-1.43; P = 0.78).
The publication bias of included studies was assessed
by the Egger’s test, and the results did not show evi-
dence of publication bias (t, 1.42; P = 0.25 for T/G vs
T/T, t, 2.62; P = 0.08 for G/G vs T carriers, and t, 2.08;
P = 0.13 for G carriers vs TT) except for G/G vs T/T
(t, 3.40; P = 0.04).
Figure 1 Association between MDM2 SNP309 and survival of patients with gastric carcinoma according to TNM classification.
(A) Kaplan-Meier survival curves of 32 patients with TNM I stage according to MDM2 SNP309 genotypes (P = 0.50). (B) Kaplan-Meier survival
curves of 101 patients with TNM II-IV stages according to MDM2 SNP309 genotypes (P < 0.01).
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It has been reported that the MDM2 SNP309G variant is
bound more efficiently by Sp1 than 309 T allele, which in-
creases MDM2 protein expression levels and weakens the
p53 function [7]. So far, no consistent conclusion has been
reached on the association between MDM2 polymorph-
ism and gastric carcinoma risk [19-23], and there has been
only one study reporting that MDM2 polymorphism is as-
sociated with both an increased susceptibility and poor
prognosis of gastric carcinoma [19]. In our present large
case–control analysis, we found that the SNP309G/G
genotype was significant associated with gastric carcinoma
risk and poor clinical prognosis. In addition, our meta-
analysis also indicated that the MDM2 SNP309G/G geno-
type was associated significantly with an increased risk ofgastric carcinoma, and provided further evidence indicat-
ing an association between this functional polymorphism
and gastric carcinoma susceptibility. We also showed
that the T to G substitution of this polymorphism signifi-
cantly enhanced the transcription activity of the MDM2
gene in vitro.
It has been reported that MDM2 SNP309 is associated
with poor prognosis of different kinds of carcinomas
[32-34], and that SNPG/G is associated with shortened
survival of patients with advanced gastric carcinoma
[19]. In agreement with previous studies, we also found
MDM2 SNP309G/G independently predicted poor prog-
nosis of gastric carcinoma.
Intriguingly, we found that individuals with both
MDM2 SNP309G/G and H. pylori infection conferred a
Figure 2 Effect of MDM2 SNP309 in the transcriptional activity
of MDM2 promoter. Data are expressed as mean and standard
deviation of three independent experiments. WT309, cells
transfected with allele 309 T; SNP309, cells transfected with allele
309 G; * P < 0.01, compared with WT309.
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an OR of 2.44, suggesting a joint effect between MDM2
polymorphism and H. pylori infection. H. pylori itself
has been identified as the cause of gastric carcinoma and
was classified as a Class I human carcinogen by the
WHO [12,35-37]. It has reported that H. pylori infection
increases the expression of MDM2 protein in the gastric
mucosa [38,39], and the overexpression inhibits p53
function of tumor suppression [5]. It has been shown
that H. pylori is able to phosphorylate and active MDM2
and subsequent degradation of p53 by activating AKT1
in gastric epithelial cells [40]. In addition, the cag PAI
also contributes to p53 inactivation because individuals
infected with H pylori cagA strains have a higher likeli-
hood of harboring p53 mutations [41]. Therefore, indi-
viduals with both MDM2 SNP309G/G genotypes and H.
pylori infection are expected to have a higher risk in de-
velopment of gastric carcinoma.Figure 3 Combined effect of transfection with MDM2 SNP309
(T > G) polymorphism and H. pylori lipopolysaccharide (LPS) on
transcriptional activity of MDM2 in AGS cell. WT309, cells
transfected with allele 309 T; SNP309, cells transfected with allele
309 G; * P < 0.01, compared with WT309 or SNP309,
where appropriate.The association of H. pylori vacuolating cytotoxin A
(VacA) or cytotoxin associated gene A protein (CagA)
with gastric carcinoma has been extensively reported
[42-44]. Recent studies have reported that LPS, another
virulence factor of H. pylori, is closely related to gastric
carcinoma [16,17]. Like E. coli LPS, H. pylori LPS is also
composed of the specific polysaccharide, core polysac-
charide and lipid A composition, and it has a certain
toxicity and immune regulation, immune stimulation.
Compared with E. coli LPS, H. pylori LPS has a lower
endotoxin activity, and the ability of stimulating macro-
phages to produce pro-inflammatory factors and the role
of nitric oxide are all weaker; however, it is the weak ac-
tivity to endotoxin that sustains chronic gastric inflam-
mation [45,46]. In the present study, we found that H.
pylori LPS elevated the transcriptional activity of the
gene MDM2, both in MDM2 WT309T and SNP309G.
It has been reported that H. pylori LPS promotes
colonization of H. pylori in the mucus layer adjacent to
the gastric epithelial surface by interacting specifically
with trefoil factor 1 in the stomach [15], and enhances
proliferation and progression of gastric carcinoma by at-
tenuating the antitumor activity and IFN- γ -mediated
cellular immunity [16,17]. Our data suggested that the
synergistic effect by MDM2 SNP309 (T > G) polymorph-
ism and H. pylori infection may attribute to H. pylori
LPS although further investigation is required.Conclusion
In conclusion, the MDM2 SNP309 polymorphism is as-
sociated with gastric carcinoma risk and poor prognosis
in Chinese patients. In addition, there is a joint effect of
MDM2 SNP309G/G allele and H. pylori infection for the
development of gastric carcinoma, which may attribute
to H. pylori LPS.Additional files
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